News/ News/ R&D France’s MedDay says drug for MS falls at phase 3 hurdle Phil Taylor central nervous system, MedDay Pharma, multiple sclerosis 0 Comment MedDay Pharma has been unable to replicate promising results with its multiple sclerosis therapy MD1003 in a confirmatory Share X France’s MedDay says drug for MS falls at phase 3 hurdle https://pharmaphorum.com/news/frances-medday-says-drug-for-ms-falls-at-phase-3-hurdle/
central nervous system, MedDay Pharma, multiple sclerosis
0 Comment
